Induced Pluripotent Stem Cell (iPSC) Market Robust Growth and High CAGR Projection by 2026

The Induced Pluripotent Stem Cell (iPSC) Market is currently valued at US$1.8 billion in the year 2022, with a projected substantial Compound Annual Growth Rate (CAGR) of 6.6% expected to continue until 2026.

The global surge in demand for innovative therapeutic approaches has driven a significant uptick in medical research endeavors worldwide. Among these, stem cell research stands as a prominent focal point. As a result, the heightened research efforts have notably contributed to the increased demand for induced pluripotent stem cells.

Download a Sample Copy of This Report -
https://www.factmr.com/connectus/sample?flag=S&rep_id=7298

Increasing investments from governments and rising prevalence of chronic diseases will further bolster iPSC market potential across the forecast period of 2022-2026. However, ethical concerns and high costs associated with stem cell research are expected to have a constraining effect on the global induced pluripotent stem cell industry through 2026.

Induced pluripotent stem cell providers are focusing on the adoption of new strategies to increase their market presence and boost revenue generation.

• In April 2022, Ncardia, a leading name in contract research, announced the launch of a new business called Cellistic, which will be entirely focused on its iPSC expertise.

The world has witnessed an increase in the incidence of neurological disorders and the demand for novel treatments for the same is also high.

Key Companies Profiled

• Sumitomo Dainippon Pharma Co. Ltd.
• FUJIFILM Cellular Dynamics Inc.
• Ncardia
• REPROCELL USA Inc.
• Takara Bio Inc.
• Thermo Fisher Scientific Inc.
• Axol Bioscience Ltd.
• ViaCyte Inc.
• Cynata Therapeutics Limited
• Pluricell Biotech
• Evotec SE
• Fate Therapeutics Inc

Key Takeaways from Market Study

• The induced pluripotent stem cell market in 2022 stands at US$ 1.8 Bn.
• From 2022 to 2026, demand for induced pluripotent stem cells is projected to surge at a CAGR of 6.6%.
• By 2026, the market is predicted to reach an approximate valuation of US$ 2.3 Bn.
• Increasing investments in research, growing establishment of contract research organizations, and rising prevalence of chronic diseases are factors that drive market potential.
• High costs of stem cell research and ethical concerns in research methodology are factors that could slow down market expansion.
• The market for induced pluripotent stem cells in the United States stands at a value of US$ 820.4 Mn.
• Consumption of induced pluripotent stem cells in China is projected to rise at a high CAGR of 8.5% from 2022 to 2026.

"Rising investments from governments to advance stem cell research are expected to favor market growth potential through 2026," says a Fact.MR analyst

Get Customization on this Report for Specific Research Solutions at:
https://www.factmr.com/connectus/sample?flag=RC&rep_id=7298

Winning Strategy

Stem cell therapy providers are increasing their investments in research and development to fast-track the development of novel treatments and therapies. Increasing investments by governments are further incentivizing iPSC providers to expand their research scope.

Induced pluripotent stem cell vendors are expected to adopt various strategies to advance their revenue generation potential across regions over the forecast period.

Embryonic stem cells, neural stem cells, umbilical cord stem cells, etc. are anticipated to see high demand in the U.S. owing to the rising popularity of stem cell therapies.

Key Segments Covered in Induced Pluripotent Stem Cell Industry Research

By Cell Type :
• Vascular Cells
• Cardiac Cells
• Neuronal Cells
• Liver Cells
• Immune Cells
• Other Cell Types
By Research Method :
• Cellular Reprogramming
• Cell Culture
• Cell Differentiation
• Cell Analysis
• Cellular Engineering
• Other Research Methods
By Application :
• Drug Development & Toxicology Testing
• Academic Research
• Regenerative Medicine
• Other Applications
By Region :
• North America
• Latin America
• Europe
• East Asia
• South Asia & Oceania
• MEA

Contact:

US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Email: sales@factmr.com

About Fact.MR

We are a trusted research partner of 80% of fortune 1000 companies across the globe. We are consistently growing in the field of market research with more than 1000 reports published every year. The dedicated team of 400-plus analysts and consultants is committed to achieving the utmost level of our client's satisfaction.

This release was published on openPR.